Advicenne
ISIN: FR0013296746 | Ticker: ALDVI | LEI: 969500YT5VMEYAYODW34
Country: France
For more than 10 years, Advicenne has been dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults with rare renal diseases.
At Advicenne we are dedicated to improving patients’ daily health and life. Our employees in France and the United States are committed to tackle the challenge of high unmet medical need to improve quality of life for patients and their caregivers.
Sibnayal® (combination of Potassium citrate and Potassium bicarbonate) was in 2021 approved by the European Medicine Agency and MHRA.
Worldwide
Headquarters3ème étage 262 Rue du Faubourg Saint-Honoré, 75008 Paris – France
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 04.10.23 | None | Other | Other | EUR 3,499,999.62 |
| 04.10.23 | None | Other | Buy | EUR 99,998.13 |
| 02.10.23 | None | Other | Other | EUR 999,998.17 |
| 21.09.23 | None | Other | Sell | EUR 22.34 |
| 15.09.23 | None | Other | Sell | EUR 13.45 |
FR0013296746
LEI969500YT5VMEYAYODW34
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.